{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:21:05Z","timestamp":1772119265223,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS KAKENHI","award":["JP18K06756"],"award-info":[{"award-number":["JP18K06756"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04774-9","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T22:59:46Z","timestamp":1743721186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The evaluation of the impact of NUDT15 variants on thiopurine metabolism in Japanese children with acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8949-1293","authenticated-orcid":false,"given":"Yoichi","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rintaro","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Ashiarai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichiro","family":"Tsuchimochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruri","family":"Hanajiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Inukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"4774_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/ped.13457","volume":"60","author":"M Kato","year":"2018","unstructured":"Kato M, Manabe A (2018) Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int 60:4\u201312","journal-title":"Pediatr Int"},{"key":"4774_CR2","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood.v93.9.2817.409k04_2817_2823","volume":"93","author":"MV Relling","year":"1999","unstructured":"Relling MV, Hancock ML, Boyett JM et al (1999) Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93:2817\u20132823. https:\/\/doi.org\/10.1182\/blood.v93.9.2817.409k04_2817_2823","journal-title":"Blood"},{"key":"4774_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01591-4","author":"LN Toksvang","year":"2022","unstructured":"Toksvang LN, Lee SHR, Yang JJ, Schmiegelow K (2022) Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Leukemia. https:\/\/doi.org\/10.1038\/s41375-022-01591-4","journal-title":"Leukemia"},{"key":"4774_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S1470-2045(17)30154-7","volume":"18","author":"SN Nielsen","year":"2017","unstructured":"Nielsen SN, Grell K, Nersting J et al (2017) DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial. Lancet Oncol 18:515\u2013524. https:\/\/doi.org\/10.1016\/S1470-2045(17)30154-7","journal-title":"Lancet Oncol"},{"key":"4774_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00007691-200008000-00002","volume":"22","author":"F Innocenti","year":"2000","unstructured":"Innocenti F, Danesi R, Favre C et al (2000) Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia. Ther Drug Monit 22:375\u2013382. https:\/\/doi.org\/10.1097\/00007691-200008000-00002","journal-title":"Ther Drug Monit"},{"key":"4774_CR6","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/jnci\/91.23.2001","volume":"91","author":"MV Relling","year":"1999","unstructured":"Relling MV, Hancock ML, Rivera GK et al (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001\u20132008. https:\/\/doi.org\/10.1093\/jnci\/91.23.2001","journal-title":"J Natl Cancer Inst"},{"key":"4774_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/bcp.12066","volume":"76","author":"L Lennard","year":"2013","unstructured":"Lennard L, Cartwright CS, Wade R et al (2013) Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. Br J Clin Pharmacol 76:125\u2013136. https:\/\/doi.org\/10.1111\/bcp.12066","journal-title":"Br J Clin Pharmacol"},{"key":"4774_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/bjh.13518","volume":"171","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Kato M, Hasegawa D et al (2015) Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br J Haematol 171:109\u2013115. https:\/\/doi.org\/10.1111\/bjh.13518","journal-title":"Br J Haematol"},{"key":"4774_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/ng.3508","volume":"48","author":"T Moriyama","year":"2016","unstructured":"Moriyama T, Nishii R, Perez-Andreu V et al (2016) NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet 48:367\u2013373. https:\/\/doi.org\/10.1038\/ng.3508","journal-title":"Nat Genet"},{"key":"4774_CR10","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FPC.0000000000000282","volume":"27","author":"T Moriyama","year":"2017","unstructured":"Moriyama T, Nishii R, Lin TN et al (2017) The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics 27:236\u2013239. https:\/\/doi.org\/10.1097\/FPC.0000000000000282","journal-title":"Pharmacogenet Genomics"},{"key":"4774_CR11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/cpt.1304","volume":"105","author":"MV Relling","year":"2019","unstructured":"Relling MV, Schwab M, Whirl-Carrillo M et al (2019) Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT 15 genotypes: 2018 update. Clin Pharmacol Ther 105:1095\u20131105. https:\/\/doi.org\/10.1002\/cpt.1304","journal-title":"Clin Pharmacol Ther"},{"key":"4774_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/FTD.0b013e318283ed5d","volume":"35","author":"H Kirchherr","year":"2013","unstructured":"Kirchherr H, Shipkova M, Von AN (2013) Improved method for therapeutic drug monitoring of 6-thioguanine nucleotides and 6-methylmercaptopurine in whole-blood by lc\/msms using isotope-labeled internal standards. Ther Drug Monit 35:313\u2013321. https:\/\/doi.org\/10.1097\/FTD.0b013e318283ed5d","journal-title":"Ther Drug Monit"},{"key":"4774_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jchromb.2016.06.017","volume":"1028","author":"SA Coulthard","year":"2016","unstructured":"Coulthard SA, Berry P, McGarrity S et al (2016) Liquid chromatography\u2013mass spectrometry for measuring deoxythioguanosine in DNA from thiopurine-treated patients. J Chromatogr B Anal Technol Biomed Life Sci 1028:175\u2013180. https:\/\/doi.org\/10.1016\/j.jchromb.2016.06.017","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"4774_CR14","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1200\/JCO.2014.59.4671","volume":"33","author":"JJ Yang","year":"2015","unstructured":"Yang JJ, Landier W, Yang W et al (2015) Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol 33:1235\u20131242. https:\/\/doi.org\/10.1200\/JCO.2014.59.4671","journal-title":"J Clin Oncol"},{"key":"4774_CR15","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1038\/s41375-018-0190-1","volume":"32","author":"S Tsujimoto","year":"2018","unstructured":"Tsujimoto S, Osumi T, Uchiyama M et al (2018) Diplotype analysis of NUDT15 variants and 6-mercaptopurine sensitivity in pediatric lymphoid neoplasms. Leukemia 32:2710\u20132714. https:\/\/doi.org\/10.1038\/s41375-018-0190-1","journal-title":"Leukemia"},{"key":"4774_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1365-2125.1983.tb02178.x","volume":"16","author":"L Lennard","year":"1983","unstructured":"Lennard L, Rees C, Lilleyman J, Maddocks J (1983) Childhood leukaemia: a relationship between intracellular 6- mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 16:359\u2013363. https:\/\/doi.org\/10.1111\/j.1365-2125.1983.tb02178.x","journal-title":"Br J Clin Pharmacol"},{"key":"4774_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00280-009-1184-5","volume":"66","author":"RL Hedeland","year":"2010","unstructured":"Hedeland RL, Hvidt K, Nersting J et al (2010) DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma. Cancer Chemother Pharmacol 66:485\u2013491. https:\/\/doi.org\/10.1007\/s00280-009-1184-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"4774_CR18","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.3324\/haematol.2020.266320","volume":"106","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Yeoh AEJ, Moriyama T et al (2021) An international retrospective study for tolerability of 6-mercaptopurine on NUDT15 bi-allelic variants in children with acute lymphoblastic leukemia. Haematologica 106:2026\u20132029. https:\/\/doi.org\/10.3324\/haematol.2020.266320","journal-title":"Haematologica"},{"key":"4774_CR19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.clpt.2003.12.001","volume":"75","author":"U Nygaard","year":"2004","unstructured":"Nygaard U, Toft N, Schmiegelow K (2004) Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 75:274\u2013281. https:\/\/doi.org\/10.1016\/j.clpt.2003.12.001","journal-title":"Clin Pharmacol Ther"},{"key":"4774_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00280-016-3151-2","volume":"78","author":"SN Nielsen","year":"2016","unstructured":"Nielsen SN, Grell K, Nersting J et al (2016) Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol 78:983\u2013994. https:\/\/doi.org\/10.1007\/s00280-016-3151-2","journal-title":"Cancer Chemother Pharmacol"},{"key":"4774_CR21","doi-asserted-by":"publisher","first-page":"872","DOI":"10.4143\/crt.2017.283","volume":"50","author":"ES Yi","year":"2018","unstructured":"Yi ES, Choi YB, Choi R et al (2018) NUDT15 variants cause hematopoietic toxicity with low 6-TGN levels in children with acute lymphoblastic leukemia. Cancer Res Treat 50:872\u2013882. https:\/\/doi.org\/10.4143\/crt.2017.283","journal-title":"Cancer Res Treat"},{"key":"4774_CR22","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/jcph.81","volume":"53","author":"MS Ebbesen","year":"2013","unstructured":"Ebbesen MS, Nersting J, Jacobsen JH et al (2013) Incorporation of 6-thioguanine nucleotides into DNA during maintenance therapy of childhood acute lymphoblastic leukemia-the influence of thiopurine methyltransferase genotypes. J Clin Pharmacol 53:670\u2013674. https:\/\/doi.org\/10.1002\/jcph.81","journal-title":"J Clin Pharmacol"},{"key":"4774_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/MPH.0000000000000733","volume":"39","author":"MS Ebbesen","year":"2017","unstructured":"Ebbesen MS, Nygaard U, Rosth\u00f8j S et al (2017) Hepatotoxicity during Maintenance Therapy and Prognosis in Children with Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol 39:161\u2013166. https:\/\/doi.org\/10.1097\/MPH.0000000000000733","journal-title":"J Pediatr Hematol Oncol"},{"key":"4774_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF00694341","volume":"25","author":"K Schmiegelow","year":"1989","unstructured":"Schmiegelow K, Schr\u00f8der H, Pulczynska MK, Hejl M (1989) Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes. Cancer Chemother Pharmacol 25:65\u201369. https:\/\/doi.org\/10.1007\/BF00694341","journal-title":"Cancer Chemother Pharmacol"},{"key":"4774_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1365-2125.1995.tb05776.x","volume":"40","author":"A Rostami-Hodjegan","year":"1995","unstructured":"Rostami-Hodjegan A, Lennard L, Lilleyman J (1995) The accumulation of mercaptopurine metabolites in age fractionated red blood cells. Br J Clin Pharmacol 40:217\u2013222. https:\/\/doi.org\/10.1111\/j.1365-2125.1995.tb05776.x","journal-title":"Br J Clin Pharmacol"},{"key":"4774_CR26","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1182\/blood-2017-11-815506","volume":"131","author":"R Nishii","year":"2018","unstructured":"Nishii R, Moriyama T, Janke LJ et al (2018) Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood 131:2466\u20132474. https:\/\/doi.org\/10.1182\/blood-2017-11-815506","journal-title":"Blood"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04774-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04774-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04774-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T22:59:49Z","timestamp":1743721189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04774-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4774"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04774-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4634919\/v1","asserted-by":"object"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Ethics Committee of each institution approved this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and human participants"}},{"value":"Written informed consent was obtained from the parents or guardians of the patients or the patients themselves, depending on the age and conceptual ability of the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"50"}}